TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19350245

Group type: EXPERIMENTAL
Intervention: Microvascular obstruction (MO)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Persistent microvascular obstruction (PMO)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Global Registry of Acute Coronary Events (GRACE) risk score
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Infarct size (IS) greater than 10%
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction less than 40%
Number of subjects: 184
Study: 16805893

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) during hemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15006955

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF), 400 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LEVO), 500 mg daily for five doses
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZI), 500 mg for one dose, then 250 mg daily for four doses
Number of subjects: 47
Study: 10844047

Group type: EXPERIMENTAL
Intervention: Hydrogel intraocular lenses
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate intraocular lenses
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lenses
Number of subjects: 93

Group type: COMPARATOR
Intervention: Comparison of visual acuity
Number of subjects: 93

Group type: COMPARATOR
Intervention: Comparison of contrast sensitivity
Number of subjects: 93
Study: 9113618

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 8240608

Group type: EXPERIMENTAL
Intervention: Cabbage leaves application
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 120
Study: 3707653

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ibopamine 50 mg t.i.d.
Number of subjects: 14
Study: 3358887

Group type: COMPARATOR
Intervention: Vigabatrin 1 g
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vigabatrin 2 g
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vigabatrin 4 g
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vigabatrin 2 g daily for 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vigabatrin 3 g daily for 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Post-treatment (1 week after stopping vigabatrin)
Number of subjects: 14
Study: 31619191

Group type: EXPERIMENTAL
Intervention: Influence of partners on attitudes toward child feeding
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Influence of partners on attitudes toward physical activity
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Influence of partners on attitudes toward television viewing
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Influence of partners on breastfeeding duration
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Influence of social connections on attitudes
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Influence of peers and family on attitudes
Number of subjects: 307
Study: 28488137

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 26

Group type: COMPARATOR
Intervention: CONT
Number of subjects: 26
Study: 25726984

Group type: EXPERIMENTAL
Intervention: Work-focused intervention (WFI)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 431
Study: 23253948

Group type: EXPERIMENTAL
Intervention: empagliflozin 50 mg q.d. for 5 days with metformin 1,000 mg b.i.d. for 3 days and 1,000 mg q.d. on Day 4
Number of subjects: 16

Group type: COMPARATOR
Intervention: metformin 1,000 mg b.i.d. for 3 days and 1,000 mg q.d. on Day 4
Number of subjects: 16
Study: 21727662

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (75 mg/day for 12 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 18371182

Group type: EXPERIMENTAL
Intervention: PCV‐plus‐RT
Number of subjects: 247

Group type: COMPARATOR
Intervention: RT
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: CFO
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: NCFO
Number of subjects: 247
Study: 16490805

Group type: EXPERIMENTAL
Intervention: 125 mg aprepitant capsule on day 1 followed by 80 mg on days 2 and 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: 125 mg and 80 mg aprepitant capsules administered in fed vs. fasted state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-day regimen of aprepitant (125 mg/80 mg/80 mg)
Number of subjects: 0
Study: 12721261

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No endocrine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide, Methotrexate, and Fluorouracil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endocrine treatment (Goserelin or Tamoxifen)
Number of subjects: 0
Study: 10714571

Group type: EXPERIMENTAL
Intervention: COL-1492 (52.5 mg N-9 gel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9373488

Group type: EXPERIMENTAL
Intervention: ETDRS method
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Probit method
Number of subjects: 70

Group type: COMPARATOR
Intervention: Line assignment method
Number of subjects: 70
Study: 1303479

Group type: EXPERIMENTAL
Intervention: Cefoperazone (1 gm per dose for 24 hours)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg per dose for 24 hours)
Number of subjects: 222

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 222
Study: 3919746

Group type: EXPERIMENTAL
Intervention: Continuous infusion of lysine acetyl salicylate (LAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous infusion of morphine
Number of subjects: 0
Study: 30850876

Group type: EXPERIMENTAL
Intervention: HELIOX with 25% helium in oxygen
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HELIOX with 50% helium in oxygen
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HELIOX with 75% helium in oxygen
Number of subjects: 44

Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 44
Study: 30571406

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No endovascular treatment (non-EVT)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ICAC volume
Number of subjects: 500
Study: 26685004

Group type: EXPERIMENTAL
Intervention: mepolizumab (100 mg, n = 9)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo (n = 8)
Number of subjects: 21
Study: 23218458

Group type: EXPERIMENTAL
Intervention: Shaping Up My Choices (SMC) programme, a 10-week school-based nutrition education curriculum
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Shaping Up My Choices (SMC) programme
Number of subjects: 938
Study: 22647518

Group type: EXPERIMENTAL
Intervention: Elinogrel (IV 80 or 120 mg followed by oral 50, 100, or 150 mg twice daily)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Elinogrel
Number of subjects: 652

Group type: COMPARATOR
Intervention: Clopidogrel (300 or 600 mg pre-procedure followed by 75 mg daily)
Number of subjects: 652
Study: 19712541

Group type: EXPERIMENTAL
Intervention: Stroke Aphasic Depression Questionnaire (SADQ H10)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Brief Assessment Schedule Depression Cards (BASDEC)
Number of subjects: 125
Study: 18243641

Group type: EXPERIMENTAL
Intervention: General cancer-related educational material plus specific information about the efficacy of ondansetron
Number of subjects: 358

Group type: COMPARATOR
Intervention: General cancer-related educational material
Number of subjects: 358
Study: 15916717

Group type: EXPERIMENTAL
Intervention: Isradipine (0 or 30 mg sustained release each evening prior to testing, plus 0 or 15 mg immediate release each morning 2 hours before cocaine infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0, 0.325, and 0.650 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cocaine (with and without isradipine)
Number of subjects: 12
Study: 12666694

Group type: EXPERIMENTAL
Intervention: Butylscopolamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: ERCP without butylscopolamine or glucagon
Number of subjects: 20
Study: 10464850

Group type: EXPERIMENTAL
Intervention: Citric acid
Number of subjects: 66

Group type: COMPARATOR
Intervention: Capsaicin
Number of subjects: 66
Study: 7832349

Group type: EXPERIMENTAL
Intervention: Midazolam and buffered lidocaine (n = 25)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo and buffered lidocaine (n = 27)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Midazolam and plain lidocaine (n = 32)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo and plain lidocaine (n = 23)
Number of subjects: 107
Study: 1976875

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Aspirin and intravenous heparin
Number of subjects: 796

Group type: COMPARATOR
Intervention: Intravenous heparin
Number of subjects: 796
Study: 230927

Group type: EXPERIMENTAL
Intervention: Clofibrate (2 g/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 28409515

Group type: EXPERIMENTAL
Intervention: Stretching condition
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study: 27451450

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum strain Bb (approximately one billion live cells daily for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 24639432

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 µg once daily
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 22335622

Group type: EXPERIMENTAL
Intervention: Low Ki67 index
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: High Ki67 index
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ki67 index (univariable analysis)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ki67 index (multivariable analysis)
Number of subjects: 128
Study: 20823393

Group type: EXPERIMENTAL
Intervention: Adjunctive cilostazol 100 mg twice daily (triple group; n=69)
Number of subjects: 134

Group type: COMPARATOR
Intervention: High maintenance-dose clopidogrel 150 mg daily (high-MD group; n=65)
Number of subjects: 134
Study: 17372807

Group type: EXPERIMENTAL
Intervention: Interactive workshop (group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Printed instruction material (group II)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Comparison of group I and group II
Number of subjects: 200
Study: 15704507

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 103
Study: 12044509

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 570

Group type: COMPARATOR
Intervention: Chondroblastic subtype
Number of subjects: 570
Study: 10021951

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 100 mg lidocaine 5% with 7.5% dextrose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with 600 mg lidocaine 2%
Number of subjects: 10
Study: 7850821

Group type: EXPERIMENTAL
Intervention: Cilazapril (CLZ) 5 mg plus Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Cilazapril (CLZ) monotherapy
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) monotherapy
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg or 25 mg
Number of subjects: 1162
Study: 2903182

Group type: EXPERIMENTAL
Intervention: Diazepam (≤30 mg/day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Double-blind, randomized, crossover single case study
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Benzodiazepine withdrawal syndrome
Number of subjects: 3
Study: 30428862

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM) treatment for 6 months
Number of subjects: 242
Study: 28232118

Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline via Turbuhaler® M2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.5 mg terbutaline via Turbuhaler® M2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline via Turbuhaler® M3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.5 mg terbutaline via Turbuhaler® M3
Number of subjects: 60
Study: 25682543

Group type: EXPERIMENTAL
Intervention: PR + P (pulmonary rehabilitation plus pedometer feedback)
Number of subjects: 27

Group type: COMPARATOR
Intervention: PR (pulmonary rehabilitation only)
Number of subjects: 27
Study: 23302012

Group type: EXPERIMENTAL
Intervention: 0.75 MAC sevoflurane
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.0 MAC sevoflurane
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.5 MAC sevoflurane
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 21492750

Group type: EXPERIMENTAL
Intervention: CMT (Chiropractic Manipulative Therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LLLT (Low-Level Laser Therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CMT + LLLT (Combination Therapy)
Number of subjects: 60
Study: 19059939

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (as an adjunct to intensive chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive chemotherapy alone (control group)
Number of subjects: 0
Study: 17043836

Group type: EXPERIMENTAL
Intervention: Treatment-naive patients
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Treatment-experienced patients
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitors resistance
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitors resistance
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Protease inhibitors resistance
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Multidrug resistance
Number of subjects: 184
Study: 12510813

Group type: EXPERIMENTAL
Intervention: IV neridronate (100 mg infused intravenously for 30 minutes every 3 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 46
Study: 11108102

Group type: EXPERIMENTAL
Intervention: Intervention group mothers received two training sessions.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intervention group adolescents
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intervention group girls
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group mothers
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group adolescents
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 9344295

Group type: EXPERIMENTAL
Intervention: FNS ambulation training using the Parastep 1 system (32 sessions)
Number of subjects: 15
Study: 7994822

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 24
Study: 2662738

Group type: EXPERIMENTAL
Intervention: APSAC (30 U over 5 minutes)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Heparin (5,000 IU in bolus injection)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 231

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 231
Study: 4920226

Group type: EXPERIMENTAL
Intervention: Tetracycline for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphamethoxazole for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloramphenicol for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purging
Number of subjects: 0
Study: 31991203

Group type: EXPERIMENTAL
Intervention: Kai-Xin-San (KXS) treatment in DPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kai-Xin-San (KXS) treatment in CUMS rats
Number of subjects: 0
Study: 31401620

Group type: EXPERIMENTAL
Intervention: Pectoral nerve blocks (Pecs block types I and II)
Number of subjects: 458
Study: 27564322

Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling (SIMS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transobturator standard midurethral sling (SMUS)
Number of subjects: 100
Study: 24670126

Group type: EXPERIMENTAL
Intervention: Home rehabilitation for mild-stroke survivors
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mild-stroke rehabilitation focusing on self-perceived health and self-perception
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Long-term follow-up in home rehabilitation services
Number of subjects: 8
Study: 22457321

Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg initial dose followed by 80 mg monthly maintenance
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg initial dose followed by 160 mg monthly maintenance
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 273
Study: 19446342

Group type: EXPERIMENTAL
Intervention: Remitted major depressive disorder (rMDD) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher depressive symptom severity
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population sample
Number of subjects: 0
Study: 18032763

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo plus dexamethasone
Number of subjects: 353
Study: 16126052

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50 mcg twice daily
Number of subjects: 342

Group type: COMPARATOR
Intervention: Montelukast (MON) 5 mg once daily
Number of subjects: 342
Study: 11840031

Group type: EXPERIMENTAL
Intervention: Soy formula with nucleotides
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Soy formula without nucleotides
Number of subjects: 267

Group type: COMPARATOR
Intervention: Human milk/formula-fed infants
Number of subjects: 267
Study: 10068868

Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP) at pathophysiological plasma levels, intravenous infusion of synthetic human CNP-22 (2 pmol kg-1 min for 2 h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7640325

Group type: EXPERIMENTAL
Intervention: 0.5 microgram ceruletide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms ceruletide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2627388

Group type: EXPERIMENTAL
Intervention: IV labetalol
Number of subjects: 20

Group type: COMPARATOR
Intervention: IV hydralazine
Number of subjects: 20
Study: 793680

Group type: EXPERIMENTAL
Intervention: Bendrofluazide and potassium chloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bendrofluazide, potassium chloride, and reserpine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Potassium chloride alone
Number of subjects: 0
Study: 31232712

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate therapy for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate therapy for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Veverimer for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Veverimer
Number of subjects: 0
Study: 28508185

Group type: EXPERIMENTAL
Intervention: AC/ixabepilone
Number of subjects: 614

Group type: COMPARATOR
Intervention: AC/paclitaxel
Number of subjects: 614
Study: 26075752

Group type: EXPERIMENTAL
Intervention: Vitamin D3 plus calcium
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study: 24107876

Group type: EXPERIMENTAL
Intervention: Lacosamide (100-400 mg per day)
Number of subjects: 56
Study: 22036019

Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 861

Group type: COMPARATOR
Intervention: Aspirin placebo
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: 600 mg aspirin (per-protocol analysis for 258 participants)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Aspirin placebo (per-protocol analysis for 250 participants)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: 600 mg aspirin (per-protocol analysis)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Aspirin placebo (per-protocol analysis)
Number of subjects: 861
Study: 19222314

Group type: EXPERIMENTAL
Intervention: Concreteness training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bogus concreteness training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study: 16234839

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540) received biannual individualised dietary counselling aimed at reduction of cardiovascular risk factors, especially saturated fat intake.
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (n = 522) did not receive dietary counselling.
Number of subjects: 1062
Study: 15669214

Group type: EXPERIMENTAL
Intervention: Serotonin-selective reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serotonin noradrenaline reuptake inhibitors (SNRIs)
Number of subjects: 0
Study: 10996350

Group type: EXPERIMENTAL
Intervention: 17beta‐oestradiol and desogestrel (17betaE(2)‐D)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens and norgestrel (CEE‐N)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 9313629

Group type: EXPERIMENTAL
Intervention: Treadmill walking at five different speeds
Number of subjects: 31
Study: 8401618

Group type: EXPERIMENTAL
Intervention: Pefloxacin 800 mg at the time of anaesthetic induction
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 3528404

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU), doxorubicin (Adriamycin), and BCNU (FAB)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 187
Study: 30043582

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine in addition to conventional Western medicine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 88